8-K: Immunic, Inc. Receives Nasdaq Delisting Warning Over Sub-$1.00 Share Price

Immunic, Inc. has received a formal notice from Nasdaq indicating non-compliance with the minimum bid price requirement, initiating a 180-day period to regain compliance or face potential delisting.

Summary

• Immunic, Inc. (IMUX) received a written notification from The Nasdaq Stock Market LLC on June 27, 2025, regarding non-compliance with Nasdaq Listing Rule 5450(a)(1).
• The non-compliance stems from the company's common stock closing bid price being below the $1.00 per share requirement for the last 30 consecutive business days.
• The company has an Initial Compliance Period of 180 calendar days, until December 24, 2025, to regain compliance.
• To regain compliance, the closing bid price of Immunic's common stock must be at least $1.00 for a minimum of 10 consecutive business days.
• If compliance is not regained by the end of the Initial Compliance Period, the company may apply for an additional compliance period, contingent on meeting other listing requirements and providing written notice of intent to cure the deficiency, potentially through a reverse stock split.
• The Notice Letter has no immediate effect on the listing of Immunic's common stock on The Nasdaq Global Select Market.

Sentiment

Score: 3

Explanation: The document indicates a significant negative event (Nasdaq non-compliance notice) which poses a material risk of delisting. While the company has a plan to address it, there is no assurance of success, reflecting a generally negative sentiment.

Negatives

• Immunic, Inc. is currently non-compliant with Nasdaq Listing Rule 5450(a)(1) due to its common stock's closing bid price falling below $1.00 per share for 30 consecutive business days.
• The company faces the risk of delisting from The Nasdaq Global Select Market if it fails to regain compliance with the minimum bid price requirement within the specified timeframe.

Risks

• Risk of delisting from The Nasdaq Global Select Market if the company fails to regain compliance with the minimum bid price requirement of $1.00 per share.
• There is no assurance that Immunic, Inc. will be able to regain compliance with the minimum bid price requirement.
• There is no assurance that the company will otherwise remain in compliance with the other listing standards for the Nasdaq Stock Market.

Future Outlook

Immunic, Inc. intends to actively monitor the closing bid price of its common stock and is evaluating available options to regain compliance with the minimum bid price requirement, including potentially effecting a reverse stock split if necessary for an additional compliance period.

Management Comments

• "The Company intends to actively monitor the closing bid price of its common stock and is evaluating available options to regain compliance with the minimum bid price requirement."

Industry Context

For a biotechnology company like Immunic, maintaining a Nasdaq listing is crucial for investor visibility, liquidity, and access to capital markets. Falling below the minimum bid price can signal investor skepticism or operational challenges, potentially hindering future fundraising and partnership opportunities. While not uncommon for smaller biotech firms, addressing this issue is paramount to maintaining market credibility and attracting institutional investment.

Stakeholder Impact

• Shareholders: Face increased risk of delisting, which could lead to reduced liquidity, lower stock price, and potential transfer to over-the-counter markets, making it harder to trade shares.

Next Steps

• Actively monitor the closing bid price of its common stock.
• Evaluate available options to regain compliance with the minimum bid price requirement.
• Potentially apply for an additional compliance period if initial compliance is not met.
• Consider effecting a reverse stock split if necessary to cure the deficiency for an additional compliance period.

Key Dates

Recommendation

Keywords

Immunic Inc., IMUX, Nasdaq, Delisting, Minimum Bid Price, Compliance, Stock Market, Reverse Stock Split, SEC Filing, 8-K